Financial Survey: Sanara MedTech (NASDAQ:SMTI) & biote (NASDAQ:BTMD)

biote (NASDAQ:BTMD) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for biote and Sanara MedTech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	2	0	2.25
Sanara MedTech	2	0	2	0	2.00

biote presently has a consensus target price of $2.75, indicating a potential upside of 36.48%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 49.24%. Given Sanara MedTech’s higher possible upside, analysts plainly believe Sanara MedTech is more favorable than biote.

Risk and Volatility

biote has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Earnings & Valuation

This table compares biote and Sanara MedTech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22 million	0.39	$27.05 million	$0.44	4.58
Sanara MedTech	$103.12 million	2.02	-$37.56 million	($3.77)	-6.04

biote has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

21.7% of biote shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares biote and Sanara MedTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Summary

biote beats Sanara MedTech on 9 of the 13 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.